[Therapeutic experience with 5-chloro-8-hydroxyquinoline].
This paper reports on the clinical trials of an antimycoticum using 5-chlorine-8-hydroxychinolin as an antimycotic agent. 142 patients with surface dermatomycoses were treated locally with the preparation for 5 to 6 weeks. Clinical and mycological healing was achieved in 68% of the cases. The results of the treatment, the epicutaneous tests and the additional UV exposition are discussed. The best results of treatment were obtained in the case of superficial dermatomycoses, in particular Trichophytia inguinalis.
D000433:1-Propanol / Q000627:therapeutic use; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use; D003881:Dermatomycoses / Q000188:drug therapy* / Q000628:therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006912:Hydroxyquinolines / Q000627:therapeutic use*; D008297:Male; D015125:Oxyquinoline / Q000627:therapeutic use*; D012459:Salicylates / Q000627:therapeutic use; D012882:Skin Tests; D014467:Ultraviolet Therapy
D000935:Antifungal Agents; D001565:Benzoates; D004338:Drug Combinations; D006912:Hydroxyquinolines; D012459:Salicylates; D015125:Oxyquinoline; D000433:1-Propanol
Therapeutische Erfahrungen mit 5-Chlor-8-Hydroxychinolin.